ML348 restores HTT-dependent BDNF transport and synaptic function by inhibiting APT1 and enhancing protein palmitoylation, exhibiting robust neuroprotective effects, thereby representing a promising candidate for HD therapy. Here, LYPLA1 is linked to Huntington disease.